Executive Wealth Management LLC boosted its stake in shares of PRA Health Sciences Inc (NASDAQ:PRAH) by 15.9% during the 2nd quarter, Holdings Channel.com reports. The firm owned 11,030 shares of the medical research company’s stock after buying an additional 1,510 shares during the quarter. Executive Wealth Management LLC’s holdings in PRA Health Sciences were worth $1,094,000 as of its most recent filing with the SEC.
A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in PRAH. BlackRock Inc. increased its stake in PRA Health Sciences by 0.9% during the first quarter. BlackRock Inc. now owns 6,211,391 shares of the medical research company’s stock worth $685,054,000 after acquiring an additional 52,524 shares during the last quarter. FMR LLC increased its stake in PRA Health Sciences by 11.3% during the first quarter. FMR LLC now owns 2,881,740 shares of the medical research company’s stock worth $317,827,000 after acquiring an additional 292,887 shares during the last quarter. Pendal Group Ltd increased its stake in PRA Health Sciences by 9.1% during the second quarter. Pendal Group Ltd now owns 898,987 shares of the medical research company’s stock worth $78,178,000 after acquiring an additional 74,844 shares during the last quarter. Frontier Capital Management Co. LLC increased its stake in PRA Health Sciences by 2.8% during the first quarter. Frontier Capital Management Co. LLC now owns 896,923 shares of the medical research company’s stock worth $98,922,000 after acquiring an additional 24,207 shares during the last quarter. Finally, NN Investment Partners Holdings N.V. increased its stake in PRA Health Sciences by 4.9% during the second quarter. NN Investment Partners Holdings N.V. now owns 860,469 shares of the medical research company’s stock worth $85,316,000 after acquiring an additional 40,436 shares during the last quarter. Institutional investors own 97.98% of the company’s stock.
A number of research analysts have recently commented on PRAH shares. Svb Leerink reaffirmed a “market perform” rating on shares of PRA Health Sciences in a research note on Tuesday, July 2nd. BidaskClub raised PRA Health Sciences from a “hold” rating to a “buy” rating in a research note on Wednesday, July 24th. Leerink Swann started coverage on PRA Health Sciences in a research note on Tuesday, July 2nd. They set a “market perform” rating and a $105.00 target price on the stock. Finally, Mizuho set a $100.00 target price on PRA Health Sciences and gave the company a “hold” rating in a research note on Friday, May 3rd. Eight investment analysts have rated the stock with a hold rating and two have given a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus price target of $113.40.
Shares of PRAH traded up $2.27 during mid-day trading on Thursday, reaching $94.75. 8,979 shares of the company’s stock traded hands, compared to its average volume of 619,701. The stock has a market capitalization of $6.11 billion, a PE ratio of 24.04, a P/E/G ratio of 1.29 and a beta of 1.12. The firm’s 50-day moving average is $98.26. PRA Health Sciences Inc has a 12 month low of $82.12 and a 12 month high of $121.98. The company has a debt-to-equity ratio of 1.11, a quick ratio of 0.99 and a current ratio of 0.99.
PRA Health Sciences (NASDAQ:PRAH) last released its earnings results on Wednesday, July 31st. The medical research company reported $1.22 EPS for the quarter, beating analysts’ consensus estimates of $1.11 by $0.11. The firm had revenue of $763.31 million for the quarter, compared to analysts’ expectations of $764.95 million. PRA Health Sciences had a return on equity of 26.64% and a net margin of 5.39%. The company’s quarterly revenue was up 5.6% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.00 earnings per share. As a group, equities research analysts forecast that PRA Health Sciences Inc will post 4.63 EPS for the current year.
About PRA Health Sciences
PRA Health Sciences, Inc, a contract research organization, provides outsourced clinical development and data solution services to the biotechnology and pharmaceutical industries worldwide. The company operates in two segments, Clinical Research and Data Solutions. The Clinical Research segment offers product registration services, including clinical trial management, project management, regulatory affairs, therapeutic expertise, clinical operations, data and programming, safety and risk management, biostatistics and medical writing, quality assurance, and late phase services.
Featured Article: How to calculate compound interest
Want to see what other hedge funds are holding PRAH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for PRA Health Sciences Inc (NASDAQ:PRAH).
Receive News & Ratings for PRA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PRA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.